https://www.selleckchem.com/pr....oducts/ly2157299.htm
BACKGROUND Chronic lung allograft dysfunction (CLAD) is still the principal long-term cause of mortality after lung transplant. Animal studies and small case series have proposed pirfenidone, a potent antifibrotic agent registered for idiopathic pulmonary fibrosis (IPF), for treatment of CLAD. The aim of this study was to evaluate the safety profile and potential efficacy of pirfenidone in patients with CLAD. MATERIAL AND METHOD The present study concerns a cohort of nine CLAD patients treated with pirfenidone. Pulmonary function test
Like
Comment
Share
